HIMS Stock Jumps 12% on Monday to $30.17 as Analyst Projects Peptides Could Hit $19B in Annual Revenue by 2030

According to FirstWave Fund CEO Jonah Lupton, Hims & Hers Health (HIMS) stock jumped over 12% on Monday to close at $30.17 amid growing optimism around peptides. Lupton projects that if Hims captures 4%-5% of the global peptide market, peptide-related revenue alone could reach $10 billion to $19 billion annually by 2030, based on his estimates of a $250 billion to $380 billion total market.

Canaccord Genuity reiterated a Buy rating and $32 price target on Hims, citing peptides as a potential long-term growth driver as the company expands into preventive healthcare and wellness. Lupton noted that the global GLP peptide market could hit 120 million to 150 million users by 2030, generating $200 billion to $300 billion in annual revenue, with non-GLP peptides adding another $50 billion to $80 billion.